Literature DB >> 8634442

Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.

L Benedetti1, F Grignani, B M Scicchitano, A M Jetten, D Diverio, F Lo Coco, G Avvisati, C Gambacorti-Passerini, S Adamo, A A Levin, P G Pelicci, C Nervi.   

Abstract

All-trans retinoic acid (t-RA) administration leads to complete remission in acute promyelocytic leukemia (APL) patients by inducing growth arrest and differentiation of the leukemic clone. In the present study, we show that t-RA treatment dramatically induced type II transglutaminase (type II TGase) expression in cells carrying the t(15;17) translocation and expressing the PML-RARalpha product such as the APL-derived NB4 cell line and fresh leukemic cells from APL patients. This induction correlated with t-RA-induced growth arrest, granulocytic differentiation, and upregulation of the leukocyte adherence receptor beta subunit (CD18) gene expression. The increase in type II TGase was not abolished by cycloheximide treatment, suggesting that synthesis of a protein intermediate was not required for the induction. t-RA did not significantly alter the rate of growth arrest and did not stimulate differentiation and type II TGase activity in NB4.306 cells, a t-RA-resistant subclone of the NB4 cell line, or in leukemic cells derived from two patients morphologically defined as APL but lacking the t(15;17). However, in NB4.306 cells, t-RA treatment was able to increase CD18 mRNA expression in a manner similar to NB4 cells. The molecular mechanisms involved in the induction of these genes were investigated. In NB4 cells, using novel receptor-selective ligands such as 9-cis-RA, TTNPB, AM580, and SR11217, we found that RAR- and RARalpha-selective retinoids were able to induce growth arrest, granulocytic differentiation, and type II TGase, whereas the RXR-selective retinoid SR11217 was inactive. Moreover, an RAR alpha-antagonist completely inhibited the expression of type II TGase and CD18 induced by these selective retinoids in NB4 cells. In NB4.306 cells, an RARalpha-dependent signaling pathway was found involved in the modulation of CD18 expression. In addition, expression of the PML-RARalpha gene in myeloid U937 precursor cells resulted in the ability of these cells to induce type II TGase in response to t-RA. On the basis of these results we hypothesize a specific involvement of a signaling pathway involving PML-RAR alpha for the induction of growth arrest, granulocytic differentiation, and type II TGase by retinoids in APL cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8634442

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Role of transglutaminase II in retinoic acid-induced activation of RhoA-associated kinase-2.

Authors:  U S Singh; M T Kunar; Y L Kao; K M Baker
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

2.  Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization.

Authors:  Jun Zhou; Laurent Pérès; Nicole Honoré; Rihab Nasr; Jun Zhu; Hugues de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

3.  Cell death induction by the acute promyelocytic leukemia-specific PML/RARalpha fusion protein.

Authors:  P F Ferrucci; F Grignani; M Pearson; M Fagioli; I Nicoletti; P G Pelicci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

4.  Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.

Authors:  L Z He; T Tolentino; P Grayson; S Zhong; R P Warrell; R A Rifkind; P A Marks; V M Richon; P P Pandolfi
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

5.  Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling.

Authors:  M Ruthardt; U Testa; C Nervi; P F Ferrucci; F Grignani; E Puccetti; F Grignani; C Peschle; P G Pelicci
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

6.  miR-638 regulates differentiation and proliferation in leukemic cells by targeting cyclin-dependent kinase 2.

Authors:  Yi Lin; Dengju Li; Qing Liang; Shangqing Liu; Xuelan Zuo; Lin Li; Xuemei Sun; Wenxin Li; Mingxiong Guo; Zan Huang
Journal:  J Biol Chem       Date:  2014-12-01       Impact factor: 5.157

7.  Hesperidin gastroresistant microparticles by spray-drying: preparation, characterization, and dissolution profiles.

Authors:  Francesca Sansone; Alessandra Rossi; Pasquale Del Gaudio; Francesco De Simone; Rita Patrizia Aquino; Maria Rosaria Lauro
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

Review 8.  Transglutaminases: nature's biological glues.

Authors:  Martin Griffin; Rita Casadio; Carlo M Bergamini
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

Review 9.  Tissue transglutaminase: a new target to reverse cancer drug resistance.

Authors:  Alfredo Budillon; Carmine Carbone; Elena Di Gennaro
Journal:  Amino Acids       Date:  2011-12-01       Impact factor: 3.520

10.  The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.

Authors:  Xi Liu; Hao Yuan; Laurent Peres; Saijuan Chen; Zhu Chen; Hugues de The; Jun Zhou; Jun Zhu
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.